VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF)-Reference-Cited by-同舟云学术

VIP elevates platelet cyclic AMP (cAMP) levels and inhibits in vitro platelet activation induced by platelet-activating factor (PAF)

Published:1984-03 Issue:2 Volume:5 Page:325-328
ISSN:0196-9781
Container-title:Peptides
language:en
Short-container-title:Peptides

Author:

Cox C.P.,Linden J.,Said S.I.

Publisher

Elsevier BV

Subject

Cellular and Molecular Neuroscience,Endocrinology,Physiology,Biochemistry

Reference24 articles.

1. VIP receptors and control of cyclic AMP production;Amiranoff,1982

2. Biosynthesis of platelet-activating factor (PAF-acether). II. Involvement of phopholipase A2 in the formation of PAF-acether and lyso-PAF-acether from rabbit platelets;Benveniste;Thromb Res,1982

3. Leukocyte-dependent histamine release from rabbit platelets. The role of IgE, basophils, and a platelet-activating factor;Benveniste;J Exp Med,1972

4. Biosynthesis of platelet-activating factor (PAF-acether): Molecular aspects of its release and its pharmacological actions;Benveniste;Int Arch Allergy Appl Immunol,1981

5. Semi-synthese et structure proposee du facteur activant les plaquettes (PAF): PAF-acether, un alkyl ether analogue de la lysophosphatidylcholine;Benveniste;C R Seances Acad Sci (III),1979

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension;Journal of Experimental Pharmacology;2021-08

2. Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension;Expert Opinion on Drug Delivery;2020-02-19

3. Emerging Novel Therapies for Heart Failure;Clinical Medicine Insights: Cardiology;2015-01

4. Therapies for pulmonary arterial hypertension: where are we today, where do we go tomorrow?;European Respiratory Review;2013-08-30

5. The specific VPAC2 agonist Bay 55-9837 increases neuronal damage and hemorrhagic transformation after stroke in type 2 diabetic rats;Neuropeptides;2013-04